Main navigation english

Canadian Public Health Association

Program

Final PROGRAM 

Download the Final Program (PDF, 2.9 MB)

Updated Friday 19 November; 11:00 EST

WEDNESDAY 8 December

Program is subject to change.

All times are Eastern Standard Time.

10:30 - 11:25

Co-developed learning activities

  • COVID-19 vaccines: Where are we? What comes next?
    • The program is co-developed with Canadian Paediatric Society and Medicago to achieve scientific integrity, objectivity and balance.
  • New and Future Technologies in Influenza Vaccines
    • The program is co-developed with AMMI Canada and Seqirus to achieve scientific integrity, objectivity and balance.
    11:25 - 11:30 Break
    11:30 - 12:30 Plenary I - Risk Communications and debunking mis- and dis-information
    12:30 - 12:45 Break

    12:45 - 13:45

    Concurrent Sessions 

    • Barriers and Opportunities to Increasing HPV Immunization for School-Aged Children in Canada
    • Oral Presentations
    13:45 - 14:30 Exhibitor Networking Break
    14:30 - 15:30

    Concurrent Sessions

    • Canada’s Vaccine Injury Support Program
    • Immunization Frameworks in Canada: A nation-wide analysis of gaps in the “system”
    • Oral Presentations
    15:30 - 15:45 Break
    15:45 - 16:45 Plenary II - The future of mRNA vaccines and seasonal influenza
    16:45 - 16:50 Break
    16:50 - 17:45

    Co-developed learning activities

    • The interplay between the COVID-19 pandemic and RSV seasonality: Current and future implications for immunoprophylaxis
      • The program is co-developed with Canadian Paediatric Society and AstraZeneca to achieve scientific integrity, objectivity and balance.
    • Protection beyond Flu: What’s New for Influenza Vaccines among Adults 50+
      • The program is co-developed with AMMI Canada and Sanofi Pasteur to achieve scientific integrity, objectivity and balance.

      THURSDAY 9 December

      All times are Eastern Standard Time.

      10:30 - 11:25

      Co-developed learning activities

      • Cervical cancer elimination in Canada by 2040: Will we get there?
        • The program is co-developed with Canadian Paediatric Society and Merck to achieve scientific integrity, objectivity and balance.
      • Evolution of mRNA vaccines from basic science to pandemic response to future prospects – the role in Canada’s immunization programs
        • The program is being co-developed with Canadian Paediatric Society and Moderna to achieve scientific integrity, objectivity and balance.
        11:25 - 11:30 Break
        11:30 - 12:30 Plenary III - Immunization and racism
        12:30 - 12:45 Break

        12:45 - 13:45

        Concurrent Sessions 

        • It’s your move: Playing your CARDs to deal with stress-related responses during pediatric vaccinations
        • Oral Presentations
        13:45 - 14:30 Exhibitor Networking Break
        14:30 - 15:30

        Concurrent Session

        • Vaccine supply chain transformation in the context of COVID-19: Lessons learned and looking forward
        • Creating a Digital Communication Channel to Vaccine-hesitant Pregnant and Parenting Canadians
        • Oral Presentations
        15:30 - 15:45 Break
        15:45 - 16:45 Plenary IV - From pandemic to endemic: The road forward
        16:45 - 16:50 Break
        16:50 - 17:45

        Co-developed learning activities

        • Pneumococcal Pneumonia and COVID-19 Pneumonia: Long-Term Outcomes
          • The program is co-developed with AMMI Canada and Pfizer Canada to achieve scientific integrity, objectivity and balance.
        • Shifting our focus to increase adult vaccination coverage: a look at the pandemic’s impact on other infectious diseases
          • The program is co-developed with AMMI Canada and GSK to achieve scientific integrity, objectivity and balance.